Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 17, Pages 4315
Publisher
MDPI AG
Online
2022-09-06
DOI
10.3390/cancers14174315
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
- (2022) Alexander E. Perl et al. BLOOD
- Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
- (2022) Marina Konopleva et al. CLINICAL CANCER RESEARCH
- Rational design and synthesis of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants
- (2022) Daseul Im et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
- (2022) Warren Fiskus et al. Blood Cancer Journal
- A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
- (2022) Ke-xin Li et al. Molecular Cancer
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
- (2021) Lauren Lee et al. HAEMATOLOGICA
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
- (2021) Abhishek Maiti et al. Blood Cancer Journal
- Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
- (2021) Jingmei Yang et al. Cancer Cell International
- FLT3-ITD allele frequency is an independent prognostic factor for poor outcome in FLT3-ITD positive AML patients
- (2021) Nevine F. Shafik et al. Clinical Lymphoma Myeloma & Leukemia
- Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia
- (2021) Junwei Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel AXL‑targeted agents overcome FLT3 inhibitor resistance in FLT3‑ITD+ acute myeloid leukemia cells
- (2021) Yi Liu et al. Oncology Letters
- Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML
- (2021) Bing Z. Carter et al. BLOOD
- The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
- (2021) Sunil K. Joshi et al. CANCER CELL
- Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
- (2021) Matteo Santoni et al. Expert Review of Anticancer Therapy
- A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
- (2021) Peihong Wang et al. Journal of Hematology & Oncology
- Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations
- (2021) Zhijie Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
- (2021) Andoni Garitano-Trojaola et al. Communications Biology
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- (2021) Lingtian Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia
- (2021) Javier Bregante et al. Cancers
- Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
- (2021) Maximilian Fleischmann et al. Cells
- LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
- (2021) Amin Huang et al. Frontiers in Oncology
- Momelotinib is a highly potent inhibitor of FLT3-mutant AML
- (2021) Mohammad Azhar et al. Blood Advances
- Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
- (2020) Catherine C. Smith et al. BLOOD
- FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia
- (2020) Jun Long et al. BLOOD
- CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
- (2020) Silvia Waldeck et al. Molecular Oncology
- Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature
- (2020) Sigal Tavor et al. HAEMATOLOGICA
- Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
- (2020) LaQuita M. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
- (2020) Ami B. Patel et al. LEUKEMIA
- Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways
- (2020) Miao Yu et al. ACTA PHARMACOLOGICA SINICA
- Phase 1 Study of combinatorial sorafenib, G‐CSF , and plerixafor treatment in relapsed/refractory, FLT3‐ITD ‐mutated acute myelogenous leukemia patients
- (2020) Gautam Borthakur et al. AMERICAN JOURNAL OF HEMATOLOGY
- Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition
- (2020) Margarita M. Dzama et al. BLOOD
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
- (2020) Motoki Eguchi et al. Biomedicines
- A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
- (2020) Catherine C. Smith et al. Blood Advances
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- (2020) Geoffrey L Uy et al. BLOOD
- Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program
- (2020) Gail J. Roboz et al. LEUKEMIA & LYMPHOMA
- Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia
- (2020) Vijaya Pooja Vaikari et al. Nanomedicine-Nanotechnology Biology and Medicine
- Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells
- (2020) Serena Travaglini et al. Blood Cancer Journal
- Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling
- (2020) Ying Xu et al. BIOMEDICINE & PHARMACOTHERAPY
- Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years
- (2019) Ying Zhang et al. ANNALS OF HEMATOLOGY
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
- (2019) Haijiao Zhang et al. Nature Communications
- Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia- dependent up-regulation of AXL
- (2019) Pierre-Yves Dumas et al. HAEMATOLOGICA
- Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
- (2019) Eunice S. Wang BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
- (2019) Jae Yoon Jeon et al. INVESTIGATIONAL NEW DRUGS
- Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration
- (2019) Yanting Duan et al. Oncology Letters
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?
- (2019) Jennifer E. Vaughn et al. Current Hematologic Malignancy Reports
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- Overcoming adaptive therapy resistance in AML by targeting immune response pathways
- (2019) Katelyn Melgar et al. Science Translational Medicine
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study
- (2019) Alexander E. Perl et al. BLOOD
- A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD
- (2019) Chunxiao Zhang et al. BLOOD
- Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms‐like tyrosine kinase 3
- (2019) Chunxiao Zhang et al. CANCER
- Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3
- (2019) Yingxiu Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cdc7 kinase stimulates Aurora B kinase in M-phase
- (2019) Sayuri Ito et al. Scientific Reports
- Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia (AML)
- (2018) Maro Ohanian et al. AMERICAN JOURNAL OF HEMATOLOGY
- Discovery of the selective and efficacious inhibitors of FLT3 mutations
- (2018) Yanle Zhi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia
- (2018) Andi Wang et al. Hematology
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
- (2018) Andrzej Lange et al. PLoS One
- FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27 Kip1 in acute myeloid leukemia
- (2017) Ines Peschel et al. HAEMATOLOGICA
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
- (2017) Bao Nguyen et al. Oncotarget
- FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27 Kip1 in acute myeloid leukemia
- (2017) Ines Peschel et al. HAEMATOLOGICA
- Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia
- (2016) Betül Oran et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
- (2016) Elie Traer et al. CANCER RESEARCH
- Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
- (2016) Mihalis S. Kariolis et al. JOURNAL OF CLINICAL INVESTIGATION
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
- (2015) C C Smith et al. LEUKEMIA
- Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
- (2015) C. C. Smith et al. Cancer Discovery
- Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes
- (2015) Salvador Alonso et al. Oncotarget
- Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
- (2015) Yi-Yu Ke et al. Scientific Reports
- Internal Tandem Duplication Mutations inFLT3Gene Augment Chemotaxis to Cxcl12 Protein by Blocking the Down-regulation of the Rho-associated Kinase via the Cxcl12/Cxcr4 Signaling Axis
- (2014) Chie Onish et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
- (2014) Mihalis S Kariolis et al. Nature Chemical Biology
- Crenolanib is a selective type I pan-FLT3 inhibitor
- (2014) C. C. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
- (2013) S. D. Baker et al. CLINICAL CANCER RESEARCH
- Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
- (2013) Karthika Natarajan et al. PLoS One
- SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML
- (2012) H. Leischner et al. BLOOD
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
- (2012) A B Williams et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
- (2010) N von Bubnoff et al. LEUKEMIA
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:
- (2009) Güliz Gürel et al. JOURNAL OF MOLECULAR BIOLOGY
- Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
- (2008) F. Breitenbuecher et al. BLOOD
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now